Zobrazeno 1 - 10
of 236
pro vyhledávání: '"Z, Mechl"'
Autor:
J. Hrbek, Petr Szturz, A. Vokáčová, Z Mechl, I Spička, P. Steyerová, M. Sýkora, J. Štork, M Zurek, Z Adam, Zdeňka Čermáková, Jiří Mayer, A Sedivá
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 27(2)
Background Schnitzler syndrome is a very rare, acquired, autoinflammatory disease of mostly adult onset with characteristic combination of chronic recurrent urticaria and monoclonal immunoglobulin M or G gammopathy predisposing the patients to malign
Autor:
S. Eckhardt, M. Nekulova, Z. Mechl, I. Hindy, R. Tomek, J. Röthig, F. Gyergyay, K. Kolaric, Decker A, I. Sawinsky, S. Kerpel-Fronius
Publikováno v:
European Journal of Haematology. 38:67-69
SUMMARY Twenty-five breast cancer patients previously not exposed to adriamycin, were treated with 30 mg/m2/day aclarubicin for four consecutive days. Out of the 19 evaluable cases 1 CR and 2 PR were observed giving an overall remission rate of 16%.
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 26(4)
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 25(6)
The primary aim of palliative treatment is to improve the quality of life, followed by prolongation of overall survival. The effective regimens are usually complicated by increased side effects, particularly hematologic. Under these conditions, usefu
Publikováno v:
Vnitrni lekarstvi. 57(3)
High-risk human papillomavirus (HPV) are implicated in the development of a subset of head and neck cancers, especially those arising from the lingual or palatine tonsils. HPV-associated cancer of the head and neck represent a different disease entit
Publikováno v:
Vnitrni lekarstvi. 57(3)
The number of malignant diseases increases and the question is why. Why is there an increasing incidence of certain cancers and why an increasing number of people dies from them? We do not have a clear answer to these questions. We just know that a d
Autor:
E. Kánitz, G. Ringwald, M. Pawlicki, E. Kaplan, J. Rolski, S. Eckhardt, Krsto Kolarić, Jacek Jassem, D. Vukas, Z. Schoket, Z. Mechl
Publikováno v:
Oncology. 49:327-332
One hundred and eleven previously untreated patients with extensive small cell lung cancer were included in a prospective randomized study with the aim to assess the efficacy and tolerance of high-dose epirubicin (120 mg/m2) in combination with eithe
Autor:
Z. Mechl, K. Kolarić
Publikováno v:
Oncology. 48:93-96
On the basis of results obtained with oral idarubicin administration in breast cancer, which have shown an established antitumor activity in approximately 28% of cases, this compound was combined with
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 21(2)
Head and neck squamous cell cancer (HNSCC) management is evolving rapidly. Approaches under exploration include induction chemotherapy, altered fractionation radiation with chemotherapy, intensity modulated radiation therapy (IMRT) and the use of bio
Autor:
A. Telekes, Bozena Sopkova, László Thurzó, Sándor Eckhardt, Z. Mechl, Marek Pawlicki, S. Kerpel-Fronius, Zoltán Hernádi
Publikováno v:
Oncology. 47:289-295
The objective of this trial was to define the antitumor activity and toxicity of etoposide for second-line treatment of patients with bulky ovarian carcinoma. Between February 1, 1986 and November 1, 1988 we recruited 82 patients. Out of them 77 (93.